Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3(4):386–90.

Article  CAS  PubMed  Google Scholar 

Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073–8.

Article  CAS  PubMed  Google Scholar 

Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975;35(5):1175–81.

CAS  PubMed  Google Scholar 

Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, et al. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem. 1989;32(3):548–55.

Article  CAS  PubMed  Google Scholar 

Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261(5118):212–5.

Article  CAS  PubMed  Google Scholar 

Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Mylotarg Study Group, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.

Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.

Article  CAS  PubMed  Google Scholar 

Norsworthy KJ, Ko CW, Lee JE, Liu J, John CS, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23(9):1103–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.

Article  CAS  PubMed  Google Scholar 

Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436–41.

Article  CAS  PubMed  Google Scholar 

Chang E, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(4):922–7.

Article  CAS  PubMed  Google Scholar 

United States Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer. April 13th, 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer (Accessed 4th February 2024)

United States Food and Drug Administration. FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma. April 3rd, 2023. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic (Accessed 4th February 2024).

United States Food and Drug Administration. FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma. December 15th, 2023. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer (Accessed 4th February 2024).

Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 Update. Eur Urol. 2022;82(5):529–42.

Article  PubMed  Google Scholar 

Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.

Article  PubMed  PubMed Central  Google Scholar 

Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open. 2022;7(6):100634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, STAR Investigators, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023;24(3):213–27.

Aweys H, Lewis D, Sheriff M, Rabbani RD, Lapitan P, Sanchez E, et al. Renal cell cancer - insights in drug resistance mechanisms. Anticancer Res. 2023;43(11):4781–92.

Article  CAS  PubMed  Google Scholar 

Boussios S, Devo P, Goodall ICA, Sirlantzis K, Ghose A, Shinde SD, et al. Exosomes in the diagnosis and treatment of renal cell cancer. Int J Mol Sci. 2023;24(18):14356.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, et al. Antibody-based therapeutics for the treatment of renal cell carcinoma: challenges and opportunities. Oncologist. 2023;28(4):297–308.

Article  PubMed  PubMed Central  Google Scholar 

Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, et al. Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res. 2018;24(18):4399–406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, et al. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020;38(6):1807–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84(2):176–90.

Article  PubMed  Google Scholar 

National Cancer Institute. Bladder cancer prognosis and survival rates. Available: https://www.cancer.gov/types/bladder/survival (Accessed February 4th 2023).

Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, et al. EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2022;81(1):95–103.

Article  PubMed  Google Scholar 

Parent P, Marcq G, Adeleke S, Turpin A, Boussios S, Rassy E, et al. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer. Ther Adv Med Oncol. 2023;15:17588359231192402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santini D, Banna GL, Buti S, Isella L, Stellato M, Roberto M. Navigating the rapidly evolving advanced urothelial carcinoma treatment landscape: insights from Italian Experts. Curr Oncol Rep. 2023;25(11):1345–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uccello M, Adeleke S, Moschetta M, Ghose A, Boussios S. Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence. Ann Palliat Med. 2023;12(6):1345–54.

Article  PubMed  Google Scholar 

Rebuzzi SE, Banna GL, Murianni V, Damassi A, Giunta EF, Fraggetta F, et al. Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: a review of the current evidence. Cancers (Basel). 2021;13(21):5517.

Article  CAS  PubMed  Google Scholar 

Maffezzoli M, Campobasso D, Rebuzzi SE, Banna GL, Fornarini G, Signori A, et al. Prognostic models for patients with metastatic urothelial carcinoma: why use them? Minerva Urol Nephrol. 2023;75(4):419–21.

Article  PubMed  Google Scholar 

Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003–13.

Article  CAS  PubMed  Google Scholar 

Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, et al. Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020;21(15):5390.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. This was the phase II EV-201 trial which led to accelerated approval of EV in mUC after progression on platinum chemotherapy and ICI.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Yu EY, Petrylak DP, O’Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–82. This trial demonstrated the benefit of EV in cisplatin eligible mUC patients as evidenced by cohort 2.

Article  CAS  PubMed  Google Scholar 

•• Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125–35. This was the landmark phase III EV-301 trial which led to full FDA approval of EV in mUC after progression on platinum chemotherapy and ICI.

Article  CAS  PubMed  PubMed Central  Google Scholar 

United States Food and Drug Administration. FDA grants accelerated approval to sacituz